Evaluating whether Ocugen, Inc. (OCGN) represents a sound investment depends entirely on an investor's personal risk tolerance, portfolio strategy, and speculative appetite for clinical-stage biotechnology stocks. Bullish investors point to its innovative gene therapy platform, supportive analyst price targets, and robust intellectual property as high-reward catalysts. Conversely, conservative investors highlight historical share price volatility, ongoing net operating losses, and the absence of massive commercial product revenues as significant risk factors requiring careful fundamental due diligence.